Prognostic factors affecting local control of hepatic tumors treated by Stereotactic Body Radiation Therapy

Sylvain Dewas, Jean-Emmanuel Bibault, Xavier Mirabel, Ingrid Fumagalli, Andrew Kramar, Hajer Jarraya, Thomas Lacornerie, Claire Dewas-Vautravers, Eric Lartigau, Sylvain Dewas, Jean-Emmanuel Bibault, Xavier Mirabel, Ingrid Fumagalli, Andrew Kramar, Hajer Jarraya, Thomas Lacornerie, Claire Dewas-Vautravers, Eric Lartigau

Abstract

Purpose: Robotic Stereotactic Body Radiation Therapy with real-time tumor tracking has shown encouraging results for hepatic tumors with good efficacy and low toxicity. We studied the factors associated with local control of primary or secondary hepatic lesions post-SBRT.

Methods and materials: Since 2007, 153 stereotactic liver treatments were administered to 120 patients using the CyberKnife® System. Ninety-nine liver metastases (72 patients), 48 hepatocellular carcinomas (42 patients), and six cholangiocarcinomas were treated. On average, three to four sessions were delivered over 12 days. Twenty-seven to 45 Gy was prescribed to the 80% isodose line. Margins consisted of 5 to 10 mm for clinical target volume (CTV) and 3 mm for planning target volume (PTV).

Results: Median size was 33 mm (range, 5-112 mm). Median gross tumor volume (GTV) was 32.38 cm3 (range, 0.2-499.5 cm3). Median total dose was 45 Gy in three fractions. Median minimum dose was 27 Gy in three fractions. With a median follow-up of 15.0 months, local control rates at one and two years were 84% and 74.6%, respectively. The factors associated with better local control were lesion size < 50 mm (p = 0.019), GTV volume (p < 0.05), PTV volume (p < 0.01) and two treatment factors: a total dose of 45 Gy and a dose-per-fraction of 15 Gy (p = 0.019).

Conclusions: Dose, tumor diameter and volume are prognostic factors for local control when a stereotactic radiation therapy for hepatic lesions is considered. These results should be considered in order to obtain a maximum therapeutic efficacy.

Figures

Figure 1
Figure 1
Local recurrence-free survival by target (A) (n = 153) and according to type of lesion (B).
Figure 2
Figure 2
Local control per target. Factors associated with better local control: a dose of 45 Gy (p = 0.019), target diameter

Figure 3

Local recurrence-free survival according to…

Figure 3

Local recurrence-free survival according to target diameter and PTV (p = 0.004).

Figure 3
Local recurrence-free survival according to target diameter and PTV (p = 0.004).
Figure 3
Figure 3
Local recurrence-free survival according to target diameter and PTV (p = 0.004).

References

    1. Ambrosino G, Polistina F, Costantin G. et al.Image-guided robotic stereotactic radiosurgery for unresectable liver metastases: preliminary results. Anticancer Res. 2009;29:3381–3384.
    1. Cárdenes HR. Role of stereotactic body radiotherapy in the management of primary hepatocellular carcinoma. Rationale, technique and results. Clin Transl Oncol. 2009;11:276–283. doi: 10.1007/s12094-009-0355-5.
    1. Goodman KA, Wiegner EA, Maturen KE. et al.Dose-escalation study of single-fraction stereotactic body radiotherapy for liver malignancies. Int J Radiat Oncol Biol Phys. 2010;78:486–493. doi: 10.1016/j.ijrobp.2009.08.020.
    1. van der Pool AEM, Méndez Romero A, Wunderink W. et al.Stereotactic body radiation therapy for colorectal liver metastases. Br J Surg. 2010;97:377–382. doi: 10.1002/bjs.6895.
    1. Bruix J, Sherman M, Llovet JM. et al.Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol. 2001;35:421–430. doi: 10.1016/S0168-8278(01)00130-1.
    1. Wulf J, Hädinger U, Oppitz U. et al.Stereotactic radiotherapy of targets in the lung and liver. Strahlenther Onkol. 2001;177:645–655. doi: 10.1007/PL00002379.
    1. Choi BO, Choi IB, Jang HS. et al.Stereotactic body radiation therapy with or without transarterial chemoembolization for patients with primary hepatocellular carcinoma: preliminary analysis. BMC Cancer. 2008;8:351. doi: 10.1186/1471-2407-8-351.
    1. Kang J-K, Kim M-S, Cho CK, Stereotactic body radiation therapy for inoperable hepatocellular carcinoma as a local salvage treatment after incomplete transarterial chemoembolization. Cancer. 2012. [published online ahead of print May 8 2012]. Accessed October 1, 2012.
    1. O’Connor JK, Trotter J, Davis GL. et al.Long-term outcomes of stereotactic body radiation therapy in the treatment of hepatocellular cancer as a bridge to transplantation. Liver Transpl. 2012;18:949–954. doi: 10.1002/lt.23439.
    1. Huang W-Y, Jen Y-M, Lee M-S. et al.Stereotactic body radiation therapy in recurrent hepatocellular carcinoma. Int J Radiat Oncol Biol Phys. 2012;84:355–361. doi: 10.1016/j.ijrobp.2011.11.058.
    1. Kopek N, Holt MI, Hansen AT, Høyer M. Stereotactic body radiotherapy for unresectable cholangiocarcinoma. Radiother Oncol. 2010;94:47–52. doi: 10.1016/j.radonc.2009.11.004.
    1. Barney BM, Olivier KR, Miller RC, Haddock MG. Clinical outcomes and toxicity using Stereotactic Body Radiotherapy (SBRT) for advanced cholangiocarcinoma. Radiat Oncol. 2012;7:67. doi: 10.1186/1748-717X-7-67.
    1. Herfarth KK, Debus J, Lohr F. et al.Stereotactic single-dose radiation therapy of liver tumors: results of a phase I/II trial. J Clin Oncol. 2001;19:164–170.
    1. Herfarth KK, Debus J. Stereotactic radiation therapy for liver metastases. Chirurg. 2005;76:564–569. doi: 10.1007/s00104-005-1039-5.
    1. Rusthoven KE, Kavanagh BD, Cardenes H. et al.Multi-institutional phase I/II trial of stereotactic body radiation therapy for liver metastases. J Clin Oncol. 2009;27:1572–1578. doi: 10.1200/JCO.2008.19.6329.
    1. McCammon R, Schefter TE, Gaspar LE. et al.Observation of a dose-control relationship for lung and liver tumors after stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys. 2009;73:112–118. doi: 10.1016/j.ijrobp.2008.03.062.
    1. Dawson LA, McGinn CJ, Normolle D. et al.Escalated focal liver radiation and concurrent hepatic artery fluorodeoxyuridine for unresectable intrahepatic malignancies. J Clin Oncol. 2000;18:2210–2218.
    1. Park HC, Seong J, Han KH. et al.Dose–response relationship in local radiotherapy for hepatocellular carcinoma. Int J Radiat Oncol Biol Phys. 2002;54:150–155.
    1. Wada H, Takai Y, Nemoto K, Yamada S. Univariate analysis of factors correlated with tumor control probability of three-dimensional conformal hypofractionated high-dose radiotherapy for small pulmonary or hepatic tumors. Int J Radiat Oncol Biol Phys. 2004;58:1114–1120. doi: 10.1016/j.ijrobp.2003.08.012.
    1. Blomgren H, Lax I, Näslund I, Svanström R. Stereotactic high dose fraction radiation therapy of extracranial tumors using an accelerator: clinical experience of the first thirty-one patients. Acta Oncol. 1995;34:861–870. doi: 10.3109/02841869509127197.
    1. Schefter TE, Kavanagh BD, Timmerman RD. et al.A phase I trial of stereotactic body radiation therapy (SBRT) for liver metastases. Int J Radiat Oncol Biol Phys. 2005;62:1371–1378. doi: 10.1016/j.ijrobp.2005.01.002.
    1. Méndez Romero A, Wunderink W, Hussain SM. et al.Stereotactic body radiation therapy for primary and metastatic liver tumors: A single institution phase i-ii study. Acta Oncol. 2006;45:831–837. doi: 10.1080/02841860600897934.
    1. Hoyer M, Roed H, Traberg Hansen A. et al.Phase II study on stereotactic body radiotherapy of colorectal metastases. Acta Oncol. 2006;45:823–830. doi: 10.1080/02841860600904854.
    1. Kavanagh BD, Schefter TE, Cardenes HR. et al.Interim analysis of a prospective phase I/II trial of SBRT for liver metastases. Acta Oncol. 2006;45:848–855. doi: 10.1080/02841860600904870.
    1. Katz AW, Carey-Sampson M, Muhs AG. et al.Hypofractionated stereotactic body radiation therapy (SBRT) for limited hepatic metastases. Int J Radiat Oncol Biol Phys. 2007;67:793–798. doi: 10.1016/j.ijrobp.2006.10.025.
    1. Tse RV, Hawkins M, Lockwood G. et al.Phase I study of individualized stereotactic body radiotherapy for hepatocellular carcinoma and intrahepatic cholangiocarcinoma. J Clin Oncol. 2008;26:657–664. doi: 10.1200/JCO.2007.14.3529.
    1. Lee MT, Kim JJ, Dinniwell R. et al.Phase I study of individualized stereotactic body radiotherapy of liver metastases. J Clin Oncol. 2009;27:1585–1591. doi: 10.1200/JCO.2008.20.0600.
    1. Cárdenes HR, Price TR, Perkins SM. et al.Phase I feasibility trial of stereotactic body radiation therapy for primary hepatocellular carcinoma. Clin Transl Oncol. 2010;12:218–225. doi: 10.1007/s12094-010-0492-x.

Source: PubMed

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

3
Abonner